Discover new cutting-edge fastGEN BCR::ABL1 Cancer kit!

fastGEN BCR::ABL1 Cancer kit for Hemato-Oncology

The fastGEN BCR::ABL1 Cancer kit is the first of its kind NGS solution designed for the precise detection of the BCR::ABL1 fusion gene.

The BCR::ABL1 fusion gene is the most important genetic marker for chronic myeloid leukemia. Patients with Philadelphia chromosome-positive leukemia patients may benefit from three generations of tyrosine kinase inhibitors.

Hyperactivation of the oncogenic tyrosine kinase ABL1 leads to cell cycle aberrations. Increased genomic instability coupled with reduced repair capacity leads to accumulation of secondary mutations, conformational changes, ineffectiveness of some tyrosine kinase inhibitors and treatment failure.

There is a need to diagnose the mutational status of these variants and their response to current treatment options and possibly develop new targeted molecular therapies. The fastGEN BCR::ABL1 Cancer kit from BioVendor Group is the first commercial NGS-based solution capable of covering the three most common breakpoint cluster regions, major, minor and micro.

• The kit covers codons 237-510
• Extraordinary sensitivity
• Major, minor and micro break-point
• Monitoring the level of minimal residual disease (MRD)

Four reasons why fastGEN is worth your attention: Fast, Simple, Reliable, Robust